224 related articles for article (PubMed ID: 30531137)
1. [Syndrome of inappropriate secretion of antidiuretic hormone in multiple myeloma patients treated with bortezomib, lenalidomide, and dexamethasone combination therapy].
Baba Y; Harada H; Shimada S; Sasaki Y; Murai S; Abe M; Fujiwara S; Arai N; Kawaguchi Y; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Saito B; Nakamaki T
Rinsho Ketsueki; 2018; 59(11):2423-2427. PubMed ID: 30531137
[TBL] [Abstract][Full Text] [Related]
2. Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine.
Escuro RS; Adelstein DJ; Carter SG
Cleve Clin J Med; 1992; 59(6):643-4. PubMed ID: 1424076
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
4. Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide.
Gilbar PJ; Richmond J; Wood J; Sullivan A
Ann Pharmacother; 2012 Sep; 46(9):e23. PubMed ID: 22911342
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma.
O'Connor-Byrne N; Glavey S; Tudor R; Murphy P; Thompson CJ; Quinn J
Exp Hematol Oncol; 2019; 8():4. PubMed ID: 30733892
[TBL] [Abstract][Full Text] [Related]
6. [Syndrome of inappropriate antidiuretic hormone secretion following adjuvant CDDP and 5-FU administration in a patient with esophageal carcinoma].
Horio T; Tsujimoto H; Akase T; Sakamoto N; Yaguchi Y; Hiraki S; Aiko S; Takechi H; Hase K; Maehara T
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1945-8. PubMed ID: 20948261
[TBL] [Abstract][Full Text] [Related]
7. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan.
Carreño A; Hernández B; Mayoralas Á; Calle C
Nefrologia; 2017; 37(5):558-559. PubMed ID: 28946972
[No Abstract] [Full Text] [Related]
8. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and adrenal insufficiency induced by rathke's cleft cyst: a case report.
Iwai H; Ohno Y; Hoshiro M; Fujimoto M; Nishimura A; Kishitani Y; Aoki N
Endocr J; 2000 Aug; 47(4):393-9. PubMed ID: 11075719
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile.
Aceituno S; Gozalbo I; Appierto M; Lizán L
Medwave; 2018 Jun; 18(3):e7220. PubMed ID: 29958267
[TBL] [Abstract][Full Text] [Related]
10. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes TM; Holstein SA; Anderson LD; Badros A; Shune L; Chari A; Pei H; Cortoos A; Patel S; Lin TS; Voorhees PM; Usmani SZ; Richardson PG
Br J Haematol; 2024 Jun; 204(6):2227-2232. PubMed ID: 38504552
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma.
Barth P; Giri S; Reagan JL; Olszewski AJ
Am J Hematol; 2021 Jan; 96(1):14-22. PubMed ID: 32918301
[TBL] [Abstract][Full Text] [Related]
12. [Syndrome of inappropriate antidiuretic hormone secretion following cisplatinum and vindesine administration in a patient with squamous cell carcinoma of the lung].
Fukabori T; Nakamura T; Kida T; Fujita Y; Goto T; Hiramori N; Fujii T; Iwasaki Y; Nakagawa M
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1213-6. PubMed ID: 2053780
[TBL] [Abstract][Full Text] [Related]
13. A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone.
Schepers AJ; Jones AR; Reeves BN; Tuchman SA; Bates JS
J Oncol Pharm Pract; 2019 Oct; 25(7):1692-1698. PubMed ID: 30501382
[TBL] [Abstract][Full Text] [Related]
14. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Uttervall K; Borg Bruchfeld J; Gran C; Wålinder G; Månsson R; Lund J; Gahrton G; Alici E; Nahi H
Eur J Haematol; 2019 Sep; 103(3):247-254. PubMed ID: 31231833
[TBL] [Abstract][Full Text] [Related]
15. Chronic idiopathic hyponatremia in an elderly patient due to inappropriate antidiuretic hormone secretion (SIADH) syndrome.
Kounatidis D; Liakopoulou C; Brozou V; Dimopoulou G; Vallianou N
Hippokratia; 2019; 23(1):42-44. PubMed ID: 32256039
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Totani H; Ri M; Kato C; Nakashima T; Suzuki N; Hagiwara S; Kanamori T; Murakami S; Masuda A; Kinoshita S; Yoshida T; Narita T; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
Int J Hematol; 2016 Mar; 103(3):316-21. PubMed ID: 26715148
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG
J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432
[TBL] [Abstract][Full Text] [Related]
18. [A case of consciousness disorder induced by the syndrome of inappropriate secretion of antidiuretic hormone following cisplatin and 5-fluorouracil chemotherapy in a patient with esophageal cancer].
Endo C; Takagawa R; Chiba T; Kawamoto M; Konishi T; Honma Y; Minami Y; Watanabe J; Morita T; Mogaki M; Masui H
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2130-2. PubMed ID: 24394036
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
Hadjiaggelidou C; Mandala E; Terpos E; Yiannaki E; Markala D; Triantafyllou T; Papatheodorou A; Gkastari V; Verrou E; Papanikolaou A; Konstantinidou P; Katodritou E
Ann Hematol; 2019 Jun; 98(6):1457-1466. PubMed ID: 30895351
[TBL] [Abstract][Full Text] [Related]
20. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and enalapril.
Castrillón JL; Mediavilla A; Méndez MA; Cavada E; Carrascosa M; Valle R
J Intern Med; 1993 Jan; 233(1):89-91. PubMed ID: 8429295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
